Practical Recommendations for Implementing Remote Patient Monitoring for Patients Receiving Bispecific Antibodies for Multiple Myeloma
Open Access
- 5 November 2026
- journal article
- Published by JMIR Publications Inc. in JMIR Cancer
- Vol. 12, e95949
Abstract
Bispecific antibodies are novel immunotherapies approved for the treatment of patients with relapsed or refractory multiple myeloma (MM). While these therapies induce deep and durable responses, they are associated with adverse events, such as cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, that require specific protocols for monitoring, prevention, and treatment. Due to the potential risk of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, current US labeling recommends inpatient administration during step-up dosing of bispecific antibodies, which typically occurs in academic centers and can often restrict the number of patients that can be treated. The administration of bispecific antibodies in the outpatient and community setting can enhance the patient experience and reduce resource use, which is a barrier to the widespread uptake of these treatments. With bispecific antibodies being evaluated in earlier lines of therapy for MM, the broader use of these agents will underscore the need for more accessible and less resource-intensive options that ensure safe outpatient administration. In this Viewpoint, we aim to provide practical recommendations built from our own real-world perspectives and case examples for institutions seeking to implement remote patient monitoring (RPM) strategies to support the outpatient dosing of bispecific antibodies in patients with MM. We discuss how the use of RPM has the potential to improve adverse event detection and management, improve patient outcomes, and decrease resource use and costs. While specific approaches will vary based on the needs of each treatment center, our experiences suggest that RPM implementation can be safe and feasible for both academic and community practices.Keywords
This publication has 38 references indexed in Scilit:
- Digital illiteracy and access to remote patient monitoring in oncology: a multicentre study of healthcare providers' perceptions and patient-reported digital literacyeClinicalMedicine, 2026
- Real World Accelerated Step-Up Dosing of Teclistamab and Talquetamab in the Outpatient Setting is Feasible and Associated with Low Incidence of Cytokine Release SyndromeClinical Lymphoma Myeloma and Leukemia, 2025
- Bispecific Outpatient Step-Up Dosing with Prophylactic Dexamethasone: The BOSS Program Experience in MyelomaClinical Lymphoma Myeloma and Leukemia, 2025
- Outpatient Step-Up Dosing of Teclistamab (TEC): An Implementation Process Shifting from the Academic Inpatient (IP) to Community Outpatient (OP) SettingClinical Lymphoma Myeloma and Leukemia, 2025
- Economic Value of Tocilizumab Prophylaxis to Prevent Cytokine Release Syndrome (CRS) during Outpatient Teclistamab (Tec) or Talquetamab (Tal) Initiation for Relapsed/Refractory Multiple Myeloma (RRMM)Clinical Lymphoma Myeloma and Leukemia, 2025
- Outcomes of Teclistamab (Tec) Step-Up Dosing in Outpatient/Hybrid Settings Among a Large Sample of Relapsed Refractory Multiple Myeloma (RRMM) Patients Treated with TecClinical Lymphoma Myeloma and Leukemia, 2025
- NCCN guidelines focus on treatment options for patients with multiple myelomaCancer, 2025
- Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudyESMO Open, 2025
- Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple MyelomaCurrent Hematologic Malignancy Reports, 2024
- Impact of academic medical center access on outcomes in multiple myelomaAmerican Journal of Hematology, 2022